Organizations
- Generate:Biomedicines
Final congress posters filed after an embargo breach describe early asthma and COPD data for GB-0895, an anti-TSLP antibody engineered for twice-yearly dosing. The studies measured safety, pharmacokinetics, and biomarkers—not clinical efficacy.
What happened
- Generate filed three final European Respiratory Society posters after draft versions appeared online before the planned embargo expired.
- In the asthma study, 69 participants received GB-0895 and 27 received placebo across single- and multiple-dose cohorts.
- The company reported no treatment-related serious adverse events and said the 300-mg dose suppressed blood eosinophils, FeNO, IL-5, and IL-13 for at least six months.
Why it matters
GB-0895 is a clinical test of whether generative protein engineering can produce a differentiated dosing profile against a validated target.
Key details
- Program
- GB-0895, an anti-TSLP antibody
- Study
- Phase 1 asthma and COPD cohorts
- Evidence
- Safety, pharmacokinetics, and biomarker results; no clinical-efficacy result
What to watch
- Clinical outcomes from the ongoing SOLAIRIA-1 (NCT07276724) and SOLAIRIA-2 (NCT07359846) Phase 3 asthma trials.
Event chronology
How the story developed
Final posters filed
Generate furnished the final GB-0895 congress posters with the SEC.
Evidence ledger
Sources behind this brief
- 01
- 02
- 03
- 04